Indefinite Delivery Contract SPE2DR25D2013

The federal contract IDV award SPE2DR25D2013 is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $999,999,999, has a period of performance from September 1, 2025 through December 31, 2036 and aims to establish a Pharmaceutical Prime Vendor Global Program to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, including the Defense Health Agency (DHA), U.S. Coast Guard, and U.S. Naval Fleet. The contract covers a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. The procurement utilizes a Lowest Price Technically Acceptable (LPTA) evaluation methodology, with the intent to make multiple regional awards to at least three different contractors to enhance resiliency and access to vital pharmaceuticals during contingencies or natural disasters.

The original solicitation, expected to be issued in March 2024, will have a 45-day open period and does not include any set-aside requirements, indicating full and open competition. The contract aims to establish a streamlined, comprehensive contracting mechanism to efficiently procure essential pharmaceutical and medical supplies to support the healthcare needs of military personnel, veterans, and other federal beneficiaries globally.